Javascript must be enabled to continue!
Abstract 1229: Neoadjuvant therapy alters collagen architecture of pancreatic cancer
View through CrossRef
Abstract
Treatment of pancreatic cancer remains clinically challenging and requires the novel therapeutic interventions to improve patient outcome. Neoadjuvant therapy i.e. preoperative treatments comprising chemotherapeutic agents with/without radiation offers down-staging and improvement of surgical resectability. Here, we report that neoadjuvant therapy alters collagen architecture of pancreatic cancer. Transcriptomic profiles of type 1 to type 28 collagens depicted changes of collagen composition due to neoadjuvant therapy. Immunohistochemically, the expressed area of collagen type 1, 3, 4, and 5 were significantly reduced post treatment. The bioinformatic approaches provided a comprehensive insight into treatment-induced matrix remodeling, which showed that Ephrin-A signaling and Ephrin-A5 appeared as a highly possible pathway and a crucial ligand. Ephrin-A5 co-localized with alpha-SMA(+) cancer-associated fibroblasts, whereby Ephrin-A5 have been implicated to synthesize collagens. The Ephrin-A5 positive cells significantly reduced after neoadjuvant therapy, also inversely correlated with tumor shrinkage rate. Using primary culture cells of cancer-associated fibroblasts, experimental exposure of radiation and chemotherapeutic agents suppressed the proliferation of cancer-associated fibroblasts, collagen synthesis and Ephrin-A5 expression. Thus, our studies demonstrate that neoadjuvant therapy down-regulates Ephrin-A5 expression, leading to a change of extracellular matrix structure. It should be a clinical concern of surgical handling when following resection.
Note: This abstract was not presented at the meeting.
Citation Format: Kosei Nakajima, Yoshinori Ino, Sotoshi Nara, Toshimitsu Iwasaki, Nobuyoshi Hiraoka. Neoadjuvant therapy alters collagen architecture of pancreatic cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1229.
American Association for Cancer Research (AACR)
Title: Abstract 1229: Neoadjuvant therapy alters collagen architecture of pancreatic cancer
Description:
Abstract
Treatment of pancreatic cancer remains clinically challenging and requires the novel therapeutic interventions to improve patient outcome.
Neoadjuvant therapy i.
e.
preoperative treatments comprising chemotherapeutic agents with/without radiation offers down-staging and improvement of surgical resectability.
Here, we report that neoadjuvant therapy alters collagen architecture of pancreatic cancer.
Transcriptomic profiles of type 1 to type 28 collagens depicted changes of collagen composition due to neoadjuvant therapy.
Immunohistochemically, the expressed area of collagen type 1, 3, 4, and 5 were significantly reduced post treatment.
The bioinformatic approaches provided a comprehensive insight into treatment-induced matrix remodeling, which showed that Ephrin-A signaling and Ephrin-A5 appeared as a highly possible pathway and a crucial ligand.
Ephrin-A5 co-localized with alpha-SMA(+) cancer-associated fibroblasts, whereby Ephrin-A5 have been implicated to synthesize collagens.
The Ephrin-A5 positive cells significantly reduced after neoadjuvant therapy, also inversely correlated with tumor shrinkage rate.
Using primary culture cells of cancer-associated fibroblasts, experimental exposure of radiation and chemotherapeutic agents suppressed the proliferation of cancer-associated fibroblasts, collagen synthesis and Ephrin-A5 expression.
Thus, our studies demonstrate that neoadjuvant therapy down-regulates Ephrin-A5 expression, leading to a change of extracellular matrix structure.
It should be a clinical concern of surgical handling when following resection.
Note: This abstract was not presented at the meeting.
Citation Format: Kosei Nakajima, Yoshinori Ino, Sotoshi Nara, Toshimitsu Iwasaki, Nobuyoshi Hiraoka.
Neoadjuvant therapy alters collagen architecture of pancreatic cancer [abstract].
In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA.
Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1229.
Related Results
Neoadjuvant Immunotherapy and Non–Small Cell Lung Cancer
Neoadjuvant Immunotherapy and Non–Small Cell Lung Cancer
Objectives:
To systematically evaluate the effectiveness and safety of neoadjuvant immunotherapy for patients with non–small cell lung cancer (NSCLC).
...
Abstract IA-08: Clinical advances in pancreas adenocarcinoma
Abstract IA-08: Clinical advances in pancreas adenocarcinoma
Abstract
Pancreatic adenocarcinoma (PDAC) remains one of the most lethal cancers today and is expected to be the second cause of cancer death in the coming decade. M...
Abstract PO-046: The effect of neoadjuvant therapy on immune profiling of pancreatic ductal adenocarcinoma: A prospective study of the PREOPANC-1 randomized controlled trial
Abstract PO-046: The effect of neoadjuvant therapy on immune profiling of pancreatic ductal adenocarcinoma: A prospective study of the PREOPANC-1 randomized controlled trial
Abstract
The randomized phase III trial (PREOPANC-1) that was performed in 16 centers in the Netherlands compared the effects of preoperative chemoradiotherapy (Gemc...
Abstract PS05-08: Restriction Spectrum Imaging MRI for automated evaluation of response to neoadjuvant therapy in breast cancer
Abstract PS05-08: Restriction Spectrum Imaging MRI for automated evaluation of response to neoadjuvant therapy in breast cancer
Abstract
Introduction:
Dynamic contrast-enhanced MRI (DCE) is currently used to evaluate neoadjuvant therapy response of breast cancer (1). However, D...
Abstract P4-06-06: Role of lymphatic SEC62 expression in prediction of treatment response in patients undergoing neoadjuvant chemotherapy for primary breast cancer
Abstract P4-06-06: Role of lymphatic SEC62 expression in prediction of treatment response in patients undergoing neoadjuvant chemotherapy for primary breast cancer
Abstract
Background Chromosome 3q26 amplifications have been shown to represent a frequent alteration in various cancer entities including breast cancer. SEC62 - a 3...
Abstract LB-80: Building Bridges for Pancreatic Cancer Research
Abstract LB-80: Building Bridges for Pancreatic Cancer Research
Abstract
Almost 40 years after President Nixon signed into law the National Cancer Act, the survival rate for pancreatic cancer has not substantially improved. Today...
Impact on CD4+ CD25High-CD127low regulatory T (Treg) cells of neoadjuvant therapy for rectal cancer patients
Impact on CD4+ CD25High-CD127low regulatory T (Treg) cells of neoadjuvant therapy for rectal cancer patients
ABSTRACT
Background:
The efficacy of neoadjuvant therapy for rectal cancer has not been assessed.
Objective:
...
Abstract P1-10-28: Role of Sec62 in prediction of response to neoadjuvant chemotherapy in patients with primary breast cancer
Abstract P1-10-28: Role of Sec62 in prediction of response to neoadjuvant chemotherapy in patients with primary breast cancer
Abstract
Background Chromosome 3q26 amplifications have been shown to represent a frequent alteration in various cancer entities including breast cancer. SEC62 - a 3...

